Funds and ETFs Cybin Inc.

Equities

CYBN

CA23256X1006

Biotechnology & Medical Research

Delayed Nyse 11:24:52 2024-05-22 am EDT 5-day change 1st Jan Change
0.3473 USD -2.14% Intraday chart for Cybin Inc. -0.77% -15.29%
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.4843 CAD
Average target price
6.089 CAD
Spread / Average Target
+1,157.38%
Consensus
  1. Stock Market
  2. Equities
  3. CYBN Stock
  4. Funds and ETFs Cybin Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW